ERBB3 and non-small cell lung carcinoma: In a dose-expansion cohort (DEC) of a phase I trial (clinical trial information: NCT03260491), HER3-DXd exhibited an objective response rate (ORR) of 39% (95% CI 24.4–54.5%) in patients with EGFR-mutated NSCLC progressed after osimertinib and platinum-based chemotherapy [186].